...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Just got off the phone with Paul Moon....

Bear right out of the American College of Cardiology (JACC):

RVX-208 lowers major adverse cardiovascular events (MACE) by 57% in diabetes mellitus (DM) patients from post-hoc analysis of phase 2 underpins an ongoing phase 3 BETonMACE trial.

 

Koo

Share
New Message
Please login to post a reply